Pfizer

News

CHMP backs Biogen’s Skyclarys for Friedreich’s ataxia

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended

News

Final obstacles in front of Pfizer, Seagen merger fall

Pfizer is expecting to close its $43 billion acquisition of antibody-drug conjugate (ADC) pioneer Seagen tomorrow, after receiving all the required regulatory approvals fo

News

ASH: Pfizer builds case for long-acting haemophilia drug

Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported

Patients

On Pfizer’s initiative to return clinical trial data to pati...

Among the most common reasons for dropping out, patients cite a lack of communication about the trial

News

Regeneron bids to join the BCMA bispecific camp

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncolog

News

Pfizer drops twice-daily obesity therapy due to side effects

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage

CHMP backs Biogen’s Skyclarys for Friedreich’s ataxia

Final obstacles in front of Pfizer, Seagen merger fall

ASH: Pfizer builds case for long-acting haemophilia drug

On Pfizer’s initiative to return clinical trial data to pati...

Regeneron bids to join the BCMA bispecific camp

Pfizer drops twice-daily obesity therapy due to side effects

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Pfizer

Editor's Picks